



a 2 1. A compound of the formula (I):



wherein R¹ is a 5- to 6- membered aromatic ring which has a group of the formula:



wherein R is a hydrogen atom or a substituted or unsubstituted hydrocarbon group,

X is a substituted or unsubstituted alkylene chain, and

Z¹ and Z² are respectively hetero-atoms, and which may have a further substituent,

the group R may bind to the 5- to 6- membered aromatic ring to form a ring,

Y is a substituted or unsubstituted imino group,

R² and R³ are respectively a substituted or unsubstituted aliphatic hydrocarbon group or a substituted or unsubstituted alicyclic heterocyclic group;

or a salt thereof.

✓

a 3 4. The compound according to claim 1, wherein the 5- to 6-membered aromatic ring is benzene.

contd.

a³ 5. The compound according to claim 1, wherein R is a halogenated or unhalogenated lower alkyl group.

6. The compound according to claim 1, wherein X is $-(CH_2)_n-$

wherein n is an integer of 1-4.

7. The compound according to claim 1, wherein Z¹ and Z² are respectively -O-, -S(O)_m-

wherein m is an integer of 0-2 or -N(R⁴)-

wherein R⁴ is a hydrogen atom or an optionally substituted lower alkyl group.

8. The compound according to claim 1, wherein Z¹ is -O- or -S(O)_m-

wherein m is an integer of 0-2.

a⁴ 10. The compound according to claim 1, wherein Z² is -O- or -N(R⁴)-

wherein R⁴ is a hydrogen atom or a substituted or unsubstituted lower alkyl group.

a⁵ 12. The compound according to claim 1, wherein Y is -N(R⁵)-

wherein R⁵ is a hydrogen atom, a substituted or unsubstituted hydrocarbon group or a substituted or unsubstituted acyl group.

13. The compound according to claim 12, wherein R⁵ is C₁₋₄ alkyl, formyl or C₂₋₅ alkanoyl.

14. The compound according to claim 12, wherein R⁵ is a group represented by the formula $-(CH_2)_kR^6$; wherein k is 0 or 1, and R⁶ is a substituted or unsubstituted 5- to 6- membered monocyclic aromatic group.

15. The compound according to claim 1, wherein R² is a substituted or unsubstituted straight

contd.

a 5

chain hydrocarbon group.

16. The compound according to claim 1, wherein R² is an optionally substituted lower alkyl group.

17. The compound according to claim 1, wherein R³ is a substituted or unsubstituted alicyclic hydrocarbon group or a substituted or unsubstituted alicyclic heterocyclic group.

✓

a 6

23. A compound selected from the group consisting of 7-(4-ethoxyethoxyphenyl)-1-ethyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 1-ethyl-7-(4-propoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-ethyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-ethoxyethoxyphenyl)-1-formyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 1-formyl-7-(4-propoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-formyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-5-yl)amino]methyl]phenyl]-1-propyl-2,3-dihydro-1-benzazepine-4-carboxamide, N-[4-[[N-methyl-N-(tetrahydropyran-5-yl)amino]methyl]phenyl]-7-(4-propoxyethoxyphenyl)-1-propyl-2,3-dihydro-1-benzazepine-4-carboxamide, 1-benzyl-7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-cyclopropylmethyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-

contd.

a⁶

(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-1-phenyl-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-(3,4-methylenedioxy)phenyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-(2-methyloxazol-5-yl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 1-allyl-7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-(3-thienyl)methyl-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-1-(thiazol-2-yl)methyl-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-(1-methylpyrazol-4-yl)methyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-(3-methylisothiazol-4-yl)methyl-N-[4-[[N-methyl-N-(tetrahydropyran-5-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-(1-ethylpyrazol-4-yl)methyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-isobutyl-N-[4-[[N-methyl-N-(tetrahydropyran-5-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 1-isobutyl-N-[4-[[N-methyl-N-(tetrahydropyran-5-yl)amino]methyl]phenyl]-7-(4-propoxyethoxyphenyl)-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-1-(thiazol-5-yl)methyl-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-1-(1-methyltetrazol-5-yl)methyl-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-1-(2-methyltetrazol-5-yl)methyl-2,3-dihydro-


100100
000000
000000
000000
000000
000000

contd.
a^b


1-benzazepine-4-carboxamide and salts thereof.

a⁷

25. A method for producing a compound of the formula I:



wherein R¹ is a 5- to 6- membered aromatic ring which has a group of the formula:



wherein R is a hydrogen atom or a substituted or unsubstituted

hydrocarbon group,

X is a substituted or unsubstituted alkylene chain, and

Z¹ and Z² are respectively hetero-atoms, and which may have a further
substituent,

the group R may bind to the 5- to 6- membered aromatic ring to form a
ring,

Y is a substituted or unsubstituted imino group,


R² and R³ are respectively a substituted or unsubstituted aliphatic hydrocarbon group or a
substituted or unsubstituted alicyclic heterocyclic group;

or a salt thereof, which comprises subjecting a


SEARCHED
INDEXED
SERIALIZED
FILED

contd.
a 7

compound of the formula:



wherein R¹ and Y are as defined above, a salt or reactive derivative thereof to a condensation reaction with a compound of the formula:



wherein R² and R³ are as defined above, or a salt thereof;

and then optionally isolating said compound of formula I or a salt thereof.

26. A pharmaceutical composition which comprises the compound according to claim 1 or a salt thereof and a pharmaceutically acceptable carrier, excipient, binder or diluent.

a 8

29. The composition according to claim 26, which is for the treatment of infectious diseases of HIV.

30. The composition according to claim 26, which for the treatment of AIDS.

a 9

35. A method for treating infectious diseases of HIV comprising administering

a pharmaceutically effective amount of a compound of claim 1 or a salt thereof

in combination with a protease inhibitor, a reverse transcriptase inhibitor or a

combination thereof

contd.

a 9

to a mammal in need thereof.

a 10

37. A method for treating AIDS comprising administering a pharmaceutically effective amount of a compound of claim 1 or a salt thereof to a mammal in need thereof.

10049331.42401